Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Approves Companion Diagnostic for Sotorasib in KRAS G12C–Mutated Advanced NSCLC

June 1st 2021

The FDA has approved the Guardant360 CDx assay as a companion diagnostic for tumor mutation profiling to identify patients with locally advanced or metastatic non–small cell lung cancer whose tumors harbor the KRAS G12C mutation and may derive benefit from sotorasib.

FDA Approves Infigratinib for FGFR2+ Cholangiocarcinoma

May 28th 2021

The FDA has approved infigratinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Artios Pharma and Novartis Set to Collaborate to Develop Next-Generation DDR Therapies

May 28th 2021

Artios Pharma, a company devoted to developing precision medicine–based treatments based on DNA damage response mechanisms, is entering into a global research collaboration with Novartis to develop next-generation DDR targets that will synergize with Novartis’ radioligand therapies.

Daiichi Sankyo and Guardant Health Team Up for Companion Diagnostic for Trastuzumab Deruxtecan in Advanced NSCLC

May 27th 2021

Daiichi Sankyo Inc. is collaborating with Guardant Health Inc. to develop a companion diagnostic for fam-trastuzumab deruxtecan-nxki, which is being studied to treat patients with advanced metastatic HER2-mutated non‒small cell lung cancer.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

FDA Approves Companion Diagnostic for Amivantamab in EGFR Exon 20–Positive NSCLC

May 25th 2021

The FDA has granted approval to the Guardant360 CDx liquid biopsy assay as the first companion diagnostic for amivantamab-vmjw to determine which patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations may derive benefit from the agent after progressing on, or after, platinum-based chemotherapy.

Larotrectinib Achieves High Marks in NTRK-Mutant Thyroid Cancer

May 24th 2021

Larotrectinib (Vitrakvi) has proved to be highly active in patients with thyroid cancer with NTRK gene fusions, exhibiting rapid and durable disease control.

Dr. Niu on Selecting Between Selpercatinib and Pralsetinib in RET Fusion+ NSCLC

May 19th 2021

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

May 18th 2021

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Selective Kinase Inhibitors Push the Envelope in RET or NTRK Fusion–Positive NSCLC

May 17th 2021

Jose Pacheco, MD, discusses key agents that have significantly improved the care of patients with NSCLC harboring RET or NTRK fusions and efforts being made to address resistance challenges.

Dr. Ross on the Utility of First- and Second-Generation EGFR Inhibitors in EGFR-Mutant NSCLC

May 13th 2021

Helen J. Ross, MD, discusses the utility of first- and second-generation EGFR inhibitors in EGFR-mutant non–small cell lung cancer.

Strategies for Targeting PI3K Proliferate

May 10th 2021

Frequently dysregulated in cancer cells, the PI3K pathway has long been a high-priority therapeutic target in oncology. However, initial efforts with pan–class I PI3K inhibitors were hampered by disappointing efficacy and substantial toxicity.

Evolving Psychosocial Care Models Step Forward as the Next Targeted Cancer Therapy

May 7th 2021

During this search for a breast cancer support system, my mother also investigated complementary therapies that peers had used to help cope with their fears, adverse effects, and feelings of helplessness.

Finding the Golden Ticket in Cholangiocarcinoma: Entering the Era of Precision Medicine

May 6th 2021

The highly heterogeneous nature of cholangiocarcinoma at the genomic, epigenetic, and molecular levels has led to the development of effective new treatments for patients with these rare malignant tumors.

TRIM63 Is a Sensitive and Specific Biomarker That May Improve Diagnosis and Treatment Selection in RCC

May 5th 2021

The cancer-specific biomarker TRIM63 was highly expressed in all classes of microphthalmia-associated transcription factor family aberration–associated renal cell carcinoma compared with other subtypes of RCC, where TRIM63 expression was low or absent.

FDA Grants Priority Review to Ivosidenib in IDH1-Mutant Cholangiocarcinoma

May 5th 2021

The FDA has granted a priority review to the supplemental new drug application for ivosidenib tablets as a treatment option for patients with previously treated, IDH1-mutant cholangiocarcinoma.

Dr. Saltos on the Importance of Broad Molecular Testing in NSCLC

April 30th 2021

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

Increased Somatically Acquired Alterations May Lead to More Aggressive Prostate Cancer, Mortality in Black Patients

April 29th 2021

A higher incidence of somatically acquired genetic alterations, including damaging mutations in ZMYM3 leading to genomic instability, as well as deletions in MAP3K7, BNIP3L, RB1, and NEIL3, and gain of MYC, may lead to more aggressive prostate cancer in Black/African American men.

TJ-CD4B Aims to Expand the Bispecific Antibody Portfolio as Phase 1 Trial Kicks Off

April 27th 2021

I-Mab Biopharma and ABL Bio, Inc set their sights on adding the bispecific antibody, TJ-CD4B, to the expanding armamentarium for patients with various types of advanced and metastatic solid cancers.

RET Inhibition Holds Tumor-Agnostic Potential

April 26th 2021

The development of novel therapies aimed at tumors with RET alterations in non-small cell lung cancer and thyroid cancers sets the stage for a future tumor-agnostic role for this molecularly targeted approach.